P. Baccam, C. Beauchemin, C. A. Macken, F. G. Hayden, and A. S. Perelson, Kinetics of Influenza A Virus Infection in Humans, Journal of Virology, vol.80, issue.15, pp.7590-7599, 2006.
DOI : 10.1128/JVI.01623-05

C. A. Beauchemin and A. Handel, A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead, BMC Public Health, vol.11, issue.Suppl 1, p.7, 2011.
DOI : 10.1186/1471-2458-11-S1-S7

L. Canini and A. S. Perelson, Viral kinetic modeling: state of the art, Journal of Pharmacokinetics and Pharmacodynamics, vol.5, issue.11, pp.431-443, 2014.
DOI : 10.1007/s10928-014-9363-3

A. Chatterjee, J. Guedj, and A. S. Perelson, Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?, Antiviral Therapy, vol.17, issue.6 Pt B, pp.1171-1182, 2012.
DOI : 10.3851/IMP2428

H. Feldmann and T. W. Geisbert, Ebola haemorrhagic fever, The Lancet, vol.377, issue.9768, pp.849-862, 2011.
DOI : 10.1016/S0140-6736(10)60667-8

Y. Furuta, K. Takahashi, M. Kuno-maekawa, H. Sangawa, S. Uehara et al., Mechanism of Action of T-705 against Influenza Virus, Antimicrobial Agents and Chemotherapy, vol.49, issue.3, pp.981-986, 2005.
DOI : 10.1128/AAC.49.3.981-986.2005

T. W. Geisbert, Emergency Treatment for Exposure to Ebola Virus, JAMA, vol.313, issue.12, pp.1221-1222, 2015.
DOI : 10.1001/jama.2015.2057

T. W. Geisbert, L. E. Hensley, P. B. Jahrling, T. Larsen, J. B. Geisbert et al., Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys, The Lancet, vol.362, issue.9400, 1953.
DOI : 10.1016/S0140-6736(03)15012-X

B. B. Gowen, E. J. Sefing, J. B. Westover, D. F. Smee, J. Hagloch et al., Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever, Antiviral Research, vol.121, pp.132-137, 2015.
DOI : 10.1016/j.antiviral.2015.07.003

J. Guedj, H. Dahari, L. Rong, N. D. Sansone, R. E. Nettles et al., Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life, Proceedings of the National Academy of Sciences, vol.110, issue.10, pp.3991-3996, 2013.
DOI : 10.1073/pnas.1203110110

F. Mentré, A. Taburet, J. Guedj, X. Anglaret, S. Keïta et al., Dose regimen of favipiravir for Ebola virus disease, The Lancet Infectious Diseases, vol.15, issue.2, pp.150-151, 2015.
DOI : 10.1016/S1473-3099(14)71047-3

M. Mohamadzadeh, L. Chen, and A. L. Schmaljohn, How Ebola and Marburg viruses battle the immune system, Nature Reviews Immunology, vol.323, issue.7, pp.556-567, 2007.
DOI : 10.1038/nri2098

A. U. Neumann, N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley et al., Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy, Science, vol.282, issue.5386, pp.103-107, 1998.
DOI : 10.1126/science.282.5386.103

L. Oestereich, A. Lüdtke, S. Wurr, T. Rieger, C. Muñoz-fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Research, vol.105, pp.17-21, 2014.
DOI : 10.1016/j.antiviral.2014.02.014

J. Olejnik, E. Ryabchikova, R. B. Corley, and E. Mühlberger, Intracellular Events and Cell Fate in Filovirus Infection, Viruses, vol.3, issue.12, pp.1501-1531, 2011.
DOI : 10.3390/v3081501

A. S. Perelson, MODELLING VIRAL AND IMMUNE SYSTEM DYNAMICS, Nature Reviews Immunology, vol.284, issue.1, pp.28-36, 2002.
DOI : 10.1006/bulm.1997.0035

A. S. Perelson and J. Guedj, Modelling hepatitis C therapy???predicting effects of treatment, Nature Reviews Gastroenterology & Hepatology, vol.47, issue.8, pp.437-445, 2015.
DOI : 10.1002/hep.24272

J. Pinheiro and D. Bates, Mixed-Effects Models in S and S-PLUS, 2006.
DOI : 10.1007/978-1-4419-0318-1

D. Safronetz, T. W. Geisbert, and H. Feldmann, Animal models for highly pathogenic emerging viruses, Current Opinion in Virology, vol.3, issue.2, pp.205-209, 2013.
DOI : 10.1016/j.coviro.2013.01.001

D. Sissoko, X. Anglaret, D. Malvy, E. Folkesson, M. Abdoul et al., Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea, 2015.

A. M. Smith, F. R. Adler, J. L. Mcauley, R. N. Gutenkunst, R. M. Ribeiro et al., Effect of 1918 PB1-F2 Expression on Influenza A Virus Infection Kinetics, PLoS Computational Biology, vol.6, issue.2, p.1001081, 2011.
DOI : 10.1371/journal.pcbi.1001081.t004

A. M. Smith and A. S. Perelson, Influenza A virus infection kinetics: quantitative data and models, Wiley Interdisciplinary Reviews: Systems Biology and Medicine, vol.5, issue.4, pp.429-445, 2011.
DOI : 10.1002/wsbm.129
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256983

S. J. Smither, L. S. Eastaugh, J. A. Steward, M. Nelson, R. P. Lenk et al., Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model, Antiviral Research, vol.104, pp.153-155, 2014.
DOI : 10.1016/j.antiviral.2014.01.012

M. A. Stafford, L. Corey, Y. Cao, E. S. Daar, D. D. Ho et al., Modeling Plasma Virus Concentration during Primary HIV Infection, Journal of Theoretical Biology, vol.203, issue.3, pp.285-301, 2000.
DOI : 10.1006/jtbi.2000.1076